Company news
Vyome Holdings, Inc. (NASDAQ:HIND) news
Vyome Holdings, Inc. news releases on 6ix. Latest, Oct 5, 2026: Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical…
Press releases & updates
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
October 5, 2026
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
September 14, 2026
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
August 25, 2026
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
July 1, 2026
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
May 27, 2026
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
May 12, 2026
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
April 22, 2026
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
April 6, 2026
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
March 25, 2026
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
February 24, 2026
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
February 18, 2026
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
February 10, 2026
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 1, 2026
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
December 22, 2025
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
December 7, 2025
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
November 24, 2025
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
November 17, 2025
Vyome Holdings Announces Results of Annual Shareholder Meeting
November 3, 2025
Vyome Holdings Acquires MIT AI Spinout Oculo Health
September 28, 2025
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
September 17, 2025
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
September 8, 2025
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
September 3, 2025
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio
August 20, 2025
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
August 17, 2025
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
August 15, 2025
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
August 13, 2025
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
August 12, 2025
Vyome Announces New Board of Directors with Deep MIT and AI Ties
August 11, 2025